These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1856404)

  • 21. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial.
    Johansen O; Brekke M; Seljeflot I; Abdelnoor M; Arnesen H
    J Am Coll Cardiol; 1999 May; 33(6):1619-26. PubMed ID: 10334433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis.
    Lambert M; Bonan R; Côté G; Crépeau J; de Guise P; Lespérance J; David PR; Waters DD
    J Am Coll Cardiol; 1988 Aug; 12(2):310-4. PubMed ID: 2969017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients.
    Gottsauner-Wolf M; Sochor H; Hornykewycz S; Beckmann R; Lang I; Probst P; Binder BR; Huber K
    Thromb Haemost; 1999 Apr; 81(4):522-6. PubMed ID: 10235432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
    Lablanche JM; McFadden EP; Meneveau N; Lusson JR; Bertrand B; Metzger JP; Legrand V; Grollier G; Macaya C; de Bruyne B; Vahanian A; Grentzinger A; Masquet C; Wolf JE; Tobelem G; Fontecave S; Vacheron A; d'Azemar P; Bertrand ME
    Circulation; 1997 Nov; 96(10):3396-402. PubMed ID: 9396433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era.
    Mercado N; Boersma E; Wijns W; Gersh BJ; Morillo CA; de Valk V; van Es GA; Grobbee DE; Serruys PW
    J Am Coll Cardiol; 2001 Sep; 38(3):645-52. PubMed ID: 11527611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
    N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local lesion-related factors and restenosis after coronary angioplasty. Evidence from a quantitative angiographic study in patients with unstable angina undergoing double-vessel angioplasty.
    de Groote P; Bauters C; McFadden EP; Lablanche JM; Leroy F; Bertrand ME
    Circulation; 1995 Feb; 91(4):968-72. PubMed ID: 7850983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors of restenosis after multivessel percutaneous transluminal coronary angioplasty.
    Le Feuvre C; Bonan R; Lespérance J; Gosselin G; Joyal M; Crépeau J
    Am J Cardiol; 1994 May; 73(12):840-4. PubMed ID: 8184804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity.
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Egeland T; Thaulow E
    Am Heart J; 2000 Mar; 139(3):482-90. PubMed ID: 10689263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and angiographic determinants of primary coronary angioplasty success. M-HEART Investigators.
    Savage MP; Goldberg S; Hirshfeld JW; Bass TA; MacDonald RG; Margolis JR; Taussig AS; Vetrovec G; Whitworth HB; Zalewski A
    J Am Coll Cardiol; 1991 Jan; 17(1):22-8. PubMed ID: 1987229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty.
    Kotamäki M; Laustiola K; Syvänne M; Heikkilä J
    J Intern Med; 1996 Nov; 240(5):293-301. PubMed ID: 8946812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial.
    Tardif JC; Côté G; Lespérance J; Gosselin G; Joyal M; de Guise P; Bilodeau L; Doucet S; Harel F; Couturier A; Gallo R; Grégoire J
    Can J Cardiol; 2001 Jan; 17(1):49-55. PubMed ID: 11173314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of vessel dilatation on restenosis after successful percutaneous transluminal coronary angioplasty.
    Schmitz HJ; Erbel R; Meyer J; von Essen R
    Am Heart J; 1996 May; 131(5):884-91. PubMed ID: 8615306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion.
    Ellis SG; Shaw RE; Gershony G; Thomas R; Roubin GS; Douglas JS; Topol EJ; Startzer SH; Myler RK; King SB
    Am J Cardiol; 1989 Apr; 63(13):897-901. PubMed ID: 2522727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty.
    Ellis SG; Roubin GS; King SB; Douglas JS; Cox WR
    Am J Cardiol; 1989 Jan; 63(1):30-4. PubMed ID: 2521196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.
    Rensing BJ; Hermans WR; Vos J; Tijssen JG; Rutch W; Danchin N; Heyndrickx GR; Mast EG; Wijns W; Serruys PW
    Circulation; 1993 Sep; 88(3):975-85. PubMed ID: 8353925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.
    Maresta A; Balducelli M; Cantini L; Casari A; Chioin R; Fabbri M; Fontanelli A; Monici Preti PA; Repetto S; De Servi S
    Circulation; 1994 Dec; 90(6):2710-5. PubMed ID: 7994812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR).
    Berger PB; Holmes DR; Ohman EM; O'Hanesian MA; Murphy JG; Schwartz RS; Serruys PW; Faxon DP
    J Am Coll Cardiol; 1996 Jan; 27(1):1-7. PubMed ID: 8522681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
    Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
    Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.